TEVA240719P20000
- 2.56
- 0.000.00%
Teva Pharmaceutical Industries Newsroom
Piper Sandler Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $20
Piper Sandler analyst David Amsellem maintains $Teva Pharmaceutical Industries(TEVA.US)$ with a buy rating, and maintains the target price at $20.According to TipRanks data, the analyst has a
UBS Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $24
UBS analyst Ashwani Verma maintains $Teva Pharmaceutical Industries(TEVA.US)$ with a buy rating, and maintains the target price at $24.According to TipRanks data, the analyst has a success rate of 47.
Express News | Teva Pharmaceuticals : UBS Raises Target Price to $24 From $22
Express News | UBS Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $24
Teva Pharmaceutical Indus Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/10/2024 41.26% UBS $22 → $24 Maintains Buy 06/27/2024 35.37% Jefferies $19 → $23 Maintains Buy 06/05/20
Argus Upgrades Teva to Buy, Cites Recent Drug Approvals
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
Argus Research Upgrades Teva Pharmaceutical Industries(TEVA.US) to Buy Rating, Announces Target Price $20
Argus Research analyst Jasper Hellweg upgrades $Teva Pharmaceutical Industries(TEVA.US)$ to a buy rating, and sets the target price at $20.According to TipRanks data, the analyst has a success rate
UBS Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $24
UBS analyst Ashwani Verma maintains $Teva Pharmaceutical Industries(TEVA.US)$ with a buy rating, and adjusts the target price from $22 to $24.According to TipRanks data, the analyst has a success
Unusual Options Activity: TEVA, MAT and Others Attract Market Bets, TEVA V/OI Ratio Reaches 347.7
EST Jul 9th Closing Delivery - In the last three hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
Daily short sale tracking: Sirius XM's short volume increased by 5 million, with a short sale ratio of 37%
Sirius XM(SIRI.US) ranked top of the list had the largest change in short volume (5.63 million shares), and the short volume ratio of FirstEnergy(FE.US) reached 37.85%. See more about the top 10 list of short selling volume changes in the latest trading day of the US stock market.
Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 A.m. ET on July 31, 2024
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2024 financial results on Wednesda
BofA Securities Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $21
BofA Securities analyst Jason Gerberry maintains $Teva Pharmaceutical Industries(TEVA.US)$ with a buy rating, and maintains the target price at $21.According to TipRanks data, the analyst has a succes
Sector Update: Health Care Stocks Slipping in Afternoon Trading
Health care stocks were declining Monday afternoon, with the NYSE Health Care Index down 0.3% and the Health Care Select Sector SPDR Fund (XLV) shedding 0.6%. The iShares Biotechnology ETF (IBB) fell
Update: Market Chatter: Teva Pharmaceuticals Faces FTC Probe on Patent Listings
(Adds details starting in second paragraph.) Teva Pharmaceutical Industries (TEVA) faces a Federal Trade Commission investigation into the company's alleged refusal to remove two dozen patents for its
Teva Focus of FTC Investigation Over Inhaler Patents
FTC Opens Investigation Into Teva Pharmaceuticals, Washington Post Reports
09:50 AM EDT, 07/01/2024 (MT Newswires) -- FTC Opens Investigation Into Teva Pharmaceuticals, Washington Post Reports Price: 16.23, Change: -0.02, Percent Change: -0.12
Vanda Will Request Relief From Court That Includes Order Requiring Defendants to Discontinue Marketing Generic Versions of HETLIOZ >VNDA
Vanda Will Request Relief From Court That Includes Order Requiring Defendants to Discontinue Marketing Generic Versions of HETLIOZ >VNDA
Vanda Intends to Proceed With Discovery in the Case to Continue Pursuing Its Claims >VNDA
Vanda Intends to Proceed With Discovery in the Case to Continue Pursuing Its Claims >VNDA
Vanda: Court Concluded Issues of Patentability Weren't Same as Those Resolved in Prior Patent-Infringement Litigation Between Parties >VNDA
Vanda: Court Concluded Issues of Patentability Weren't Same as Those Resolved in Prior Patent-Infringement Litigation Between Parties >VNDA